“Goldman Sachs Predicts up to 165% Surge for These 2 ‘Strong Buy’ Stocks”
July 31, 2024
“…RegenXBio (RGNX)
The first Goldman pick we’ll look at is RegenXBio, a gene therapy company specializing in single-dose treatments for severe diseases with few or no existing therapies…. Choi rates RGNX a Buy along with a $38 price target. This figure indicates room for a one-year upside of 165%. (To watch Choi’s track record, click here)…
Viridian Therapeutics (VRDN)
The second stock on today’s list is Viridian Therapeutics, a biotech firm whose work focuses on the development of novel treatments for autoimmune diseases… Along with that Buy rating, Law gives Viridian shares a $23 price target, suggesting a 38% upside over a one-year horizon. (To watch Law’s track record, click here)…”
https://finance.yahoo.com/news/goldman-sachs-predicts-165-surge-130927486.html